Skip to main content

Posts

Developing Software: What Should Academic Researchers Keep in Mind? (Part 2)

In Part 1   of this essay, I discussed three learning points I'd gained from my encounters with faculty-developed software in my work as a technology transfer officer at an academic medical research institution. Those points were as follows:  Patents aren't a necessary prerequisite for commercializing software Be deliberate in your use of third-party code If you are going to release your source code publicly, consider doing it under a restrictive open source license When I finished writing it, I knew I had more to say on the topic. You can read Part 1 here . Below is my continuation. 4 - Figuring out the ‘thing’ that’s going to be licensed An important part of handing off a software-based technology from university to private industry is to first figure out exactly what is being handed off. This can be tricky! I’ve discovered that software, as a commercial asset, can take many forms. The licensing professional can bring a lot of clarity to the negotiations by making sure both t
Recent posts

Developing Software: What Should Academic Researchers Keep in Mind? (Part 1)

Having never had any experience in software development when I entered the world of academic technology transfer back in 2013, I never expected to learn so much in the intervening years about software licensing and commercialization. It turns out that, even working in technology transfer at a medical institution, I encounter a surprising number of software-based technologies. Furthermore, with the recent rise in the use of AI/ML applications in biomedical research, the frequency at which I am presented with software in my work is only increasing.  Below is my first attempt at summarizing what I have learned thus far in managing software assets within an academic technology transfer setting. None of what I write here should be viewed as constituting legal advice. Furthermore, if you are an academic researcher, you should most definitely rely on the guidance you receive from your own institution’s own technology transfer office when navigating these waters! However, I’m sharing my observ

Comics About Patents (A Work In Progress)

Back in January and February of 2018, I spent some time creating two four-panel comics about the process of 1) obtaining patent protection, and 2) monetizing those patent rights by licensing them. I drew the comics to serve as an illustration of concepts that I often find myself explaining to others in the course of my work. I've already shared these comics through  Twitter  and  Facebook  (click on either of link to see more of the creative process!). However, I thought I'd share them with my blog's readership as well. Please enjoy! I'm really hoping to reignite this project at some point in the future and create more episodes. (Click on the images below to enlarge) Episode 1: Episode 2: - Isamu Hartman

What Texas can learn from Israel: Takeaways from the Texas-Israel Alliance Healthcare & Life Sciences Innovation Conference

This past Friday (Oct. 25, 2019) the Texas-Israel Alliance held its  Healthcare & Life Sciences Innovation Conference , which was conveniently hosted by UT Southwestern Medical Center, where I work. The event presented 5~6 panel discussions and fireside chats that featured speakers from a wide variety of institutions and business entities including the FDA, Microsoft, Rabin Medical Center, NASA, Start-up Nation Central, several venture capital firms, and others. All of the featured talks were of uniformly high quality, but one stood out for me in terms of 1) delivering insights into what makes the Israeli innovation ecosystem unique, and 2) providing lessons that can be derived from those insights that may be useful for further developing Texas's own ecosystem. This was the fireside chat between Guy Hilton , General Manager of Start-up Nation Central , and Dr. Claire Aldridge , Associate Vice President of Commercialization and Business Development at UT Southwestern (who, in t

Corporate Venture Capital at the Top 10 Pharma/Biotech Companies

Today I'm taking a step outside of Texas and looking at the world. Many large pharmaceutical and biotech firms maintain venture capital operations through which they invest in early-stage biomedical companies. I wanted to get a sense of what these biopharma corporate venture capital (CVC) funds are up to. Which companies have CVC funds? How active are they? What are their goals? What are they investing in? Background: general and sector-specific trends in venture capital In 2014 venture capital funding in the U.S. hit its highest annual mark since 2001, as investors participated in $47.3 billion across 3,617 deals . Within this trend Life Sciences was the second largest sector (behind only the Media and Entertainment sector) for 2014 in dollar terms with $8.6 billion invested in 789 deals, the highest level since 2007 . Corporate venture funding has followed similar trends:  2014 marked the strongest year for CVC activity since 2000 with $5.4 billion invested in U.S.-based co